Pharmacotherapy of atrial fibrillation in COVID-19 patients
Abstract
The coronavirus pandemic disease 2019 (COVID-19) has changed the face of contemporary medicine. However, each and every medical practitioner must be aware of potential early and late complications of COVID-19, its impact on chronic diseases — especially ones as common as atrial fibrillation (AF) — and the possible interactions between patients’ chronic medications and pharmacotherapy of COVID-19. Patients with AF due to comorbidities and, often, elderly age are assumed to be at a higher risk of a severe course of COVID-19. This expert consensus summarizes the current knowledge regarding the pharmacotherapy of AF patients in the setting of the COVID-19 pandemic. In general, anticoagulation principles in quarantined or asymptomatic individuals remain unchanged. Nevertheless, it is advisable to switch from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants (NOACs) whenever possible due to their consistent benefits and safety with fixed dosing and no monitoring. Additionally, in AF patients hospitalized due to mild or moderate COVID-19 pneumonia, we recommend continuing NOAC treatment or to switching to low-molecular-weight heparin (LMWH). On the other hand, in severely ill patients hospitalized in intensive care units, intravenous or subcutaneous dosing is preferable to oral, which is why the treatment of choice is either LMWH or unfractionated heparin. Finally, particularly in critical scenarios, the treatment strategy in COVID-19 patients with AF should be individualized based on possible interactions between anticoagulants, antiarrhythmics, antivirals, and antibiotics. In this consensus, we also discuss how to safely perform COVID-19 vaccination in anticoagulated AF patients.
Keywords: atrial fibrillationcoronavirusinfectionsevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2)coronavirus disease 2019 (COVID-19)non-vitamin K antagonist oral anticoagulants (NOACs)direct oral anticoagulants (DOACs)
References
- Richardson S, Hirsch J, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new york city area. JAMA. 2020; 323(20): 2052–2059.
- Li J, He X, Zhang W, et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control. 2021; 49(1): 82–89.
- Ambrus DB, Benjamin EJ, Bajwa EK, et al. Risk factors and outcomes associated with new-onset atrial fibrillation during acute respiratory distress syndrome. J Crit Care. 2015; 30(5): 994–997.
- Inciardi R, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020; 41(19): 1821–1829.
- Gopinathannair R, Merchant FM, Lakkireddy DR, et al. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol. 2020; 59(2): 329–336.
- Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in italy. JAMA. 2020; 323(18): 1775–1776.
- Porter AL, Margolis AR, Staresinic CE, et al. Feasibility and safety of a 12-week INR follow-up protocol over 2 years in an anticoagulation clinic: a single-arm prospective cohort study. J Thromb Thrombolysis. 2019; 47(2): 200–208.
- Steffel J, Collins R, Antz M, et al. 2021 european heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021.
- Tomaszuk-Kazberuk A, Kołtowski L, Balsam P, et al. Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation - Messages from the 2018 EHRA. Cardiol J. 2018; 25(4): 423–440.
- Hermans C, Lambert C. Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis. J Thromb Haemost. 2020; 18(7): 1794–1795.
- Gawałko M, Kapłon-Cieślicka A, Hohl M, et al. COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications. Int J Cardiol Heart Vasc. 2020; 100631.
- Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844–847.
- Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemos. 2020; 18(5): 1094–1099.
- Papakonstantinou PE, Borovac JA, Gąsecka A, et al. Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy? Eur J Prev Cardiol. 2021 [Epub ahead of print].
- Fabrizi F, Alfieri CM, Cerutti R, et al. COVID-19 and acute kidney injury: a systematic review and meta-analysis. Pathogens. 2020; 9(12).
- Wojtowicz D, Tomaszuk-Kazberuk A, Małyszko J, et al. Hematuria and other kinds of bleedings on non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation: an updated overview on occurrence, pathomechanisms and management. Wiad Lek. 2020; 73(11): 2528–2534.
- Ozen M, Yilmaz A, Cakmak V, et al. D-Dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med. 2021; 40: 55–59.
- Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020; 8: 49.
- Flisiak R, Horban A, Jaroszewicz J, et al. Management of SARS-CoV- infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. Pol Arch Intern Med. 2021; 131(5): 487–496.
- The Liverpool Drug Interaction Group (University of Liverpool, U., University Hospital of Basel (Switzerland) and Radboud UMC (Netherlands). [Internet]. Interactions with Experimental COVID-19 Therapies, 2021. http://www.covid19-druginteractions.org (cited 2021 May 1).
- RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285): 1637–1645.
- PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021; 397(10279): 1063–1074.
- O'Connor S. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10274): 605–612.
- Furtado R, Berwanger O, Fonseca H, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020; 396(10256): 959–967.
- Hu YF, Cheng WH, Hung Y, et al. Management of atrial fibrillation in COVID-19 pandemic. Circ J. 2020; 84(10): 1679–1685.
- Gillis AM, Kates RE. Clinical pharmacokinetics of the newer antiarrhythmic agents. Clin Pharmacokinet. 1984; 9(5): 375–403.
- Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984; 9(2): 136–156.
- Russo V, Rago A, Carbone A, et al. Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications. J Cardiovasc Pharmacol. 2020; 76(2): 138–145.
- Naccarelli G, Wolbrette D, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol. 2003; 91(6): 15–26.
- Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007; 27(6): 874–887.
- Iisalo E. Clinical pharmacokinetics of digoxin. Clin Pharmacokinet. 1977; 2(1): 1–16.
- Rattanawong P, Shen W, El Masry H, et al. Guidance on short-term management of atrial fibrillation in coronavirus disease 2019. J Am Heart Assoc. 2020; 9(14): e017529.
